top of page
LATEST NEWS
Stem Cell Breakthrough Lets Paralyzed Patient Stand Again
Japanese researchers restored movement in a paralyzed man using reprogrammed stem cells injected into his spinal-cord injury. The treatment, tested in four patients, helped one man stand independently and another regain limb movement, offering early evidence that iPS cell therapies may support neural repair and future paralysis treatments.
2 days ago
Scientists Cure Type 1 Diabetes in Mice Using a Gentle Immune System “Reset”
Stanford Medicine researchers cured Type 1 diabetes in mice using a gentle immune-reset approach that combines donor blood stem cells and pancreatic islet transplants. The method prevented autoimmunity, required no immunosuppressive drugs, and may pave the way for future treatments for diabetes and other autoimmune diseases.
3 days ago
Orforglipron Weight-Loss Pill Trial Results: Eli Lilly Reports 12.4% Body Weight Reduction, Shares Fall 15%
Eli Lilly’s once-daily oral weight-loss pill, orforglipron, helped patients lose 12.4% of their body weight in a Phase 3 trial, but fell short of rival Wegovy’s results. The announcement sent Lilly shares down 15%, the company’s steepest drop in 25 years, despite meeting all primary and secondary endpoints and showing improvements in heart health markers.
Aug 11
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance Gene Editing for Heart Disease
Eli Lilly has announced its $1.3 billion acquisition of Verve Therapeutics, a leading biotech company specializing in gene editing for cardiovascular diseases. This strategic move aims to accelerate the development of one-time gene therapies using base editing technology, targeting high-risk heart disease patients. The deal marks a significant step forward in Eli Lilly’s expansion into precision genetic medicine.
Jul 20
Base Editor Gene Therapy for CPS1 Deficiency Treats Baby’s Rare Disorder
In a historic first, doctors used base editor gene therapy to treat a baby with CPS1 deficiency, a rare genetic liver disorder. The personalized treatment—delivered using lipid nanoparticles—led to improved ammonia levels and reduced medication needs. Unlike traditional CRISPR, base editing made precise DNA changes without cutting, offering a safer, more targeted option. This breakthrough marks a major step forward in treating rare diseases with gene-editing technology.
Jul 1
Light-Induced Gene Therapy Using Nanoparticles Targets and Destroys Cancer Cells' Mitochondria
A groundbreaking new approach in cancer treatment has emerged, utilizing light to disable the mitochondria, the energy-producing...
Feb 8
Gene and Cell Therapy Clinical Trials to Notice in 2025
Several clinical trials in 2025 are pushing the boundaries of gene and cell therapy, aiming to address a range of complex diseases. Below...
Jan 31
Five-Year Follow-Up Shows Sustained Visual Improvements in LHON Patients Treated with AAV Gene Therapy
A recent international study has shown that lenadogene nolparvovec, a gene therapy based on adeno-associated virus (AAV), can provide...
Dec 27, 2024
CRISPR Gene-Editing Therapies Make Strides, but Cost and Accessibility Remain Key Challenges
As CRISPR-based therapies edge closer to becoming mainstream, groundbreaking treatments for blood disorders and cancer are making their...
Dec 19, 2024
StitchR: New Technology for Treating Genetic Diseases with Large Genes
Gene therapy has shown promise in treating many genetic diseases, but some conditions, like muscular dystrophy, involve very large genes...
Nov 18, 2024
AI Creates Precise DNA “Switches” for Gene Therapy - A Step Closer to Targeted Treatments
Imagine controlling genes with the precision of a light switch— controlling specific parts of the body as you will. That’s what the...
Oct 23, 2024
New Gene-Editing Technique: A Better Alternative to CRISPR for Fixing Cystic Fibrosis Mutation
A team from the Broad Institute of MIT and Harvard, along with Harvard University and the Howard Hughes Medical Institute, has made...
Sep 10, 2024
Two New CRISPR-Based Gene Therapies for Sickle Cell Anemia Approved by the FDA
The FDA recently approved two groundbreaking CRISPR-based gene therapies for curing Sickle Cell Disease (SCD): Casgevy - developed by...
Mar 25, 2024
Revolutionary Gene Therapy Targeting Galectin 1 Shows Promise in Reducing Liver Cancer Incidence in Animal Models
New Approach for Liver Cancer Treatment and Possible Prevention: Gene Therapy Targets Biomarker for Hepatocellular Carcinoma (HCC)...
Feb 2, 2024
bottom of page